findmyKOL
Clinical trialNCT01002417CompletedPhase 2/PHASE3Interventional

MCS in the Treatment of Lower Urinary Tract Symptoms

SponsorHealth Ever Bio-Tech Co., Ltd.Enrollment274Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Allan J Pantuck, MD, MS, FACS

    University of California, Los Angeles

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • David Geffen School of Medicine at Ucla

    Los Angeles, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MCS-2 15 mg/dayMCS-2 30 mg/dayPlacebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2010
Primary completion
28 Feb 2014
Completion
28 Feb 2014
Last update posted
3 Mar 2015
Registered enrollment
274
Registry id
NCT01002417

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.